 | |
| Clinical data | |
|---|---|
| Other names | PD-0200390; PD-200390; PD0200390; PD200390 |
| Routes of administration | Oral[1] |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C10H19NO2 |
| Molar mass | 185.267 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Atagabalin (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name; developmental code namePD-0200390) is a drug developed byPfizer and related togabapentin, which similarly binds to the α2δcalcium channels (1 and2).[1][2] It was under development as a treatment forinsomnia, but was discontinued following unsatisfactory trial results.[1][3][4][5][6] The drug reachedphase 2clinical trials for this indication prior to the discontinuation of its development.[1]
